102 results
8-K
ORTX
Orchard Therapeutics plc
24 Jan 24
Termination of a Material Definitive Agreement
4:17pm
contributions or social security contributions. The Unvested Cash Consideration and the Unvested CVR Consideration will vest and be paid pursuant
8-K
EX-2.2
ORTX
Orchard Therapeutics plc
24 Jan 24
Termination of a Material Definitive Agreement
4:17pm
Contribution in the United Kingdom (or corresponding social security contribution in any other jurisdiction)) from any Equity Award CVR Payment, Purchaser
DEFA14A
ORTX
Orchard Therapeutics plc
30 Nov 23
Additional proxy soliciting materials
4:13pm
the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (X; formerly Twitter and LinkedIn … and may include additional social media channels. The contents of Orchard’s website or these channels, or any other website that may be accessed from its
8-K
EX-99.1
ORTX
Orchard Therapeutics plc
30 Nov 23
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
4:06pm
with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (X … investor relations website and may include additional social media channels. The contents of Orchard’s website or these channels, or any other
DEFM14A
ORTX
Orchard Therapeutics plc
16 Nov 23
Proxy related to merger
4:45pm
Insurance contributions or social security contributions, (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise … income tax and employee National Insurance contributions or social security contributions, (i) an amount in cash equal to the Cash Consideration and (ii
8-K
EX-99.1
2h3a9y6zy30h0fvd
13 Nov 23
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
7:05am
PREM14A
mov3 k5k5fbc
3 Nov 23
Preliminary proxy related to merger
5:11pm
8-K
EX-99.1
o1ynf7b3sxyfmixi4 c1
26 Oct 23
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
4:35pm
DEFA14A
igmb0
17 Oct 23
Additional proxy soliciting materials
4:32pm
DEFA14C
upmj5gybmurfns2a ks6
5 Oct 23
Additional information
4:43pm
DEFA14A
vau66u
5 Oct 23
Additional proxy soliciting materials
9:07am
8-K
EX-2.1
skkgevqy
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
EX-10.1
evs7ybu3qo6z96e mu
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
uteg7envhhyy
5 Oct 23
Kyowa Kirin to Acquire Orchard Therapeutics
9:05am
8-K
EX-99.1
d2gl5deob1
18 Sep 23
Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review
7:07am
8-K
EX-99.1
aly0au2
3 Aug 23
Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA
7:05am
8-K
EX-99.1
exfhip2kpa7hv1iv
26 Jun 23
Resulting in $34 Million of Additional Capital
7:06am
8-K
EX-99.1
0gbnl9s5c5r9oc ot
23 May 23
Regulation FD Disclosure
7:06am